MK-0616
InvestigationalAlso known as: Merck PCSK9 Inhibitor, Oral PCSK9
An oral macrocyclic peptide PCSK9 inhibitor in Phase 3 development by Merck. The CORALreef trial program is enrolling approximately 17,000 patients. Phase 2 data showed greater than 60% LDL-C reduction. Would be the first oral peptide-based PCSK9 drug if approved.
Research Statistics
Large Phase 3 program. Strong mechanism. High commercial potential.
Research Dossier
Overview
What is MK-0616 and what does the research say?
How It Works (Simplified)
MK-0616 is an oral macrocyclic peptide that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), a protein that degrades LDL receptors on liver cells. By blocking PCSK9, MK-0616 increases the number of LDL receptors available to clear LDL cholesterol from the blood. Unlike existing injectable PCSK9 inhibitors (evolocumab, alirocumab), MK-0616 achieves this through oral administration — a significant advance for patient adherence.
Scientific Pathways
PCSK9 Inhibition: MK-0616 binds to PCSK9 in the circulation, preventing it from binding to and degrading hepatic LDL receptors. This increases LDL receptor density on hepatocytes, enhancing LDL-C clearance from plasma.
Macrocyclic Peptide Technology: The compound uses a constrained macrocyclic peptide scaffold that provides oral bioavailability — typically a major challenge for peptide therapeutics. This technology platform could enable oral delivery of other peptide drugs.
Clinical Evidence
Phase 2 Data: A randomized, double-blind Phase 2 trial demonstrated greater than 60% reduction in LDL-C from baseline with MK-0616, comparable to injectable PCSK9 inhibitors. Results were presented at ACC (American College of Cardiology) and published in peer-reviewed journals.
CORALreef Phase 3 Program: The CORALreef cardiovascular outcomes program is enrolling approximately 17,000 patients across multiple global sites. This is one of the largest cardiovascular outcomes trials currently underway and will evaluate both LDL-C reduction and hard cardiovascular endpoints (MACE).
Safety Profile
Phase 2 data showed MK-0616 was generally well tolerated with a safety profile comparable to placebo. No significant hepatic, renal, or musculoskeletal safety signals were identified. The oral route eliminates injection site reactions associated with current PCSK9 inhibitors. Full safety characterization awaits Phase 3 completion.
Important Limitations
- Phase 3 ongoing; no pivotal efficacy data yet available
- Cardiovascular outcomes data pending (CORALreef program)
- Oral bioavailability of peptides can vary with food and GI conditions
- Long-term safety beyond Phase 2 duration not yet characterized
- Not available outside clinical trials
- Commercial viability depends on cost competitiveness with generic statins
References
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Related Peptides
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Cardiogen
AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
Chelohart
Heart cytamin, Cardiac peptide supplement, A-7 heart peptides
A cytamin-class peptide supplement derived from cardiac (heart) tissue, part of the Khavinson bioregulator framework. Marketed as an oral supplement for cardiac health support. Contains peptide complexes rather than defined sequences. Very limited clinical validation, primarily Russian-language literature.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.